Probing the role of point mutations in the cyp51A gene from Aspergillus fumigatus in the model yeast Saccharomyces cerevisiae. by Alcazar-Fuoli, L. et al.
Medical Mycology April 2011, 49, 276–284 Probing the role of point mutations in the cyp51A 
gene from Aspergillus fumigatus in the model yeast 
Saccharomyces cerevisiae  Received  12  May  2010 ; Receiv
Accepted  30  July  2010 
 L. Alcazar-Fuoli present addre
rial College London, Centre for
Armstrong Road, London, UK.
Correspondence: Emilia Mell
Nacional de Microbiologia, In
Majadahonda-Pozuelo Km2, 282
fax:   34 91 5097919; E-mail: em
 L.  ALCAZAR-FUOLI * ,  E.  MELLADO * ,  M.  CUENCA-ESTRELLA *  &  D.  SANGLARD †  
 * Mycology Reference Laboratory, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain, 
and   †  Institute of Microbiology, University of Lausanne and University Hospital Center, Lausanne, Switzerland 
© 2011 ISHAM  Azole-resistant strains of  Aspergillus fumigatus have been detected and the underlying 
molecular mechanisms of resistance characterized. Point mutations in the  cyp51 A gene 
have been proved to be related to azole resistance in  A. fumigatus clinical strains and 
with different resistance profi les depending on the amino acid change (G54E, G54V, 
G54R, G54W, M220V, M220K, M220T, M220I). The aim of this work was to express 
 A. fumigatus  cyp51 A genes in the yeast  Saccharomyces cerevisiae in order to better 
assess the contribution of each independent amino acid substitution to resistance. A tet-
racycline regulatable system allowing repression of the endogenous essential  ERG11 
gene was used. The expression of  Aspergillus  cyp 51A alleles could effi ciently restore 
the absence of  ERG11 in  S. cerevisiae. In general,  S. cerevisiae clones expressing. 
A. fumigatus  cyp 51A alleles from azole-resistant isolates showed higher MICs to all 
azoles tested than those expressing alleles from susceptible isolates. The azole suscepti-
bility profi les obtained in  S. cerevisiae upon expression of specifi c  cyp51 A alleles reca-
pitulated susceptibility profi les observed from their  A. fumigatus origins. In conclusion 
this work supports the concept that characteristics of specifi c  A. fumigatus  cyp 51A alle-
les could be investigated in the heterologous host  S. cerevisiae . 
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resistance  Introduction 
 Invasive fungal diseases are an increasingly common 
complication in critically ill patients and often with fatal 
outcomes [1].  Candida species are the most common cause 
of fungal infections followed by  Aspergillus spp. [2,3]. 
Among the latter,  A. fumigatus is the main causative agent 
of invasive disease, normally affecting immunocompro-
mised patients with persistent neutropenia suffering severe 
hematological malignancies or transplant recipients [4]. ed in fi nal revised form 27 July 2010; 
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ellado@isciii.es Despite the improvement and the development of novel 
antifungals, the mortality due to invasive aspergillosis 
remains very high [1,5]. The status of the host immune sys-
tem is a critical parameter that will determine the outcome 
of fungal infections. However, other factors such as antifun-
gal resistance might have a signifi cant impact on the 
outcome of the infection. Triazole drug resistance in 
 A. fumigatus is an emerging problem that has been docu-
mented in environmental strains and during azole therapy 
[6,7]. 
 Most  A.  fumigatus strains are susceptible to the avail-
able antifungals used for the treatment of patients with 
invasive infections [8,9]. However,  A. fumigatus strains 
with secondary resistance to azole drugs have been described 
and their resistance mechanisms have been thoroughly 
studied. 
 The cytochrome P450 14- α sterol demethylase, encoded 
by  cyp 51A gene (ERG11 in yeast), is the azole drugs target 
and responsible, at least in part, for the azole drugs ’ affi nity DOI: 10.3109/13693786.2010.512926
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 Table 1  Aspergillus fumigatus strains used in this study with their 
respective Cyp51A amino acid substitutions and their azole susceptibility 
profi les.  
Strains Amino acid change MICs mg/L References
 A. fumigatus Cyp51A ITZ VRZ POS
CM237 – 0.25 0.5 0.06 –
CM2158 M220V   8 2 0.5 [13]
CM2159 M220K   8 1.2 2 [13]
CM2161 G54E   8 0.35 0.5 [12]
CM2162 G54V   8 0.25 0.35 [12]
CM2164 M220T   8 0.76 0.33 [13]
CM2266 G54W   8 0.71 16 [12]
ITZ8 G54R   8 0.5 0.5 [12]
PW6 M220I   8 0.25-1 0.5-1 [13]
 Table 2  Saccharomyces cerevisiae strains used in this study. 
Strain Genotype Parent References
DSY3886  MAT a  ura3-52 leu2 Δ 1 
his3 Δ 200 GAL2 CMVp( tetR ’ -
SSN6 ):: LEU2 trp1 ::Tta
– [16]
DSY3899  MAT a  ura3-52 leu2 Δ 1 
his3 Δ 200 GAL2 CMVp( tetR ’ -
SSN6 ):: LEU2 trp1 ::Tta 
ERG11 ::kanMX- tet O 7 
DSY3886 This work
DSY3961  MAT a  ura3-52 leu2 Δ 1 
his3 Δ 200 GAL2 CMVp( tetR ’ -
SSN6 ):: LEU2 trp1 ::Tta  
ERG11 ::kanMX- tet O 7 
pdr5 Δ ::HIS3kanMX
DSY3899 This workin  A. fumigatus [10]. Azole-resistant  A. fumigatus isolates 
of clinical origin have been found to have different muta-
tions that are responsible for the increase in their azole 
MICs [11 – 14]. Different resistance profi les can be mainly 
attributed to single amino acid substitutions in Cyp51A. 
One mutation is at position glycine 54 including amino 
acid changes G54E, G54V, G54R, or G54W. Clinical 
strains with these mutations showed resistance to itracon-
azole and high MICs to posaconazole but not to voricon-
azole or ravuconazole [12]. The second important mutation 
is at methionine 220 including amino acid changes M220V, 
M220K, M220T and M220I [13], which yield resistance 
to itraconazole and reduced susceptibility to posaconazole, 
voriconazole and ravuconazole. However, the functional 
characterization of the individual contribution of each 
 cyp 51A mutation to azole resistance has never been tested 
for  A. fumigatus . 
 In the present study, the wild type  cyp51 A and the dif-
ferent altered  cyp51 A alleles from susceptible and resistant 
 A. fumigatus strains were expressed in the yeast  Saccharo-
myces cerevisiae in order to address the role of each on 
azole resistance. 
 The heterologous expression of  A. fumigatus cyp 51A 
was performed by conditional expression of the yeast 14- α 
sterol demethylase gene ( ERG11 ) and induced expression 
of several  cyp 51A cDNAs from  A. fumigatus. A tetracy-
cline regulatable system [15,16] which allows repression 
of gene expression was used. Since  ERG11 is essential in 
 S. cerevisiae , this key system can test the Cyp51A func-
tional complementation by growth restoration. The differ-
ent yeast isolates containing each single  cyp 51A gene were 
used to asses the differences in azole drugs interaction 
between different mutated alleles. 
 Material and methods 
 Strains and growth conditions 
 A total of nine A. fumigatus strains were used in this work. 
Their identifi cation names together with their  cyp51 A 
genetic background are indicated in Table 1. Their minimal 
inhibitory concentrations (MICs) to itraconazole, voricon-
azole and posaconazole obtained from previous studies 
[12,13] are summarized in Table 1.  S. cerevisiae strains 
used in this work are listed in Table 2. 
 A. fumigatus strains were grown at 37 ° C in potato dex-
trose agar (Oxoid, Madrid, Spain) or malt extract agar 
(MEA). Conidia stocks were preserved in sterile distilled 
water at 4 ° C.  S. cerevisiae strains were grown either in 
complete medium YEPD, containing 1% Bacto peptone 
(Difco), 0.5% yeast extract (Difco) and 2% glucose (Fluka) 
or in minimal media containing yeast nitrogen base (YNB) 
with 2% glucose (Fluka, Buchs, Switzerland) and without © 2011 ISHAM, Medical Mycology, 49, 276–284amino acids (Difco), but complemented with all bases and 
amino acids except for selection without uracil (YNB-ura) 
or histidine (YNB-his). Selective media to induce expres-
sion media consisted in YNB-ura, 2% galactose (Fluka) 
and doxycycline (2 mg/ml) (Sigma). When isolates were 
grown on solid media, 2% agar (Difco) was added to each 
medium. 
 DNA preparations for transformation 
 All DNA oligonucleotides were purchased from Eurogen-
tec S.A. (Belgium). The expression vector pYES2/CT was 
purchased from Invitrogen (Lausanne, Switzerland). Linear 
plasmids used for transformation were prepared in accord 
with the following procedure. Five  μ g of plasmid DNA 
were digested with HindIII and XhoI. After digestion the 
linear plasmid was precipitated with two volumes of etha-
nol 100% and 0.1 volume of 3M sodium acetate. After 
centrifugation, digested plasmids were washed once with 
70% ethanol and dissolved in 10 ml of TE buffer. PCR 
products for transformation were prepared in the same 
way. 
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 The  Saccharomyces cerevisiae strains used in this work 
were: (i) strain DSY3886 derived from Y40122 ( MAT a 
 ura3-52 leu2 Δ 1 his3 Δ 200 GAL2 CMVp( tetR ’ -SSN6 ):: LEU2 
 trp1 ::Tta); and (ii) strain DSY3899, derived from DSY3886 
but with  ERG11 under the control of doxycycline 
( ERG11 ::kanMX- tet O 7 ). To place the  ERG11 promoter 
under control of the  Tet system in  S. cerevisiae DSY3886, 
a linear DNA fragment was obtained from a PCR with 
pMC324 as a template and primers P1 (5 ′ -GCAGCGC
ACATACAATGTGCGTGCAAGATTTGCCGGGTT
GGACAACGTACGCTGCAGGTCGACGG-3 ′ ) and P2 
(5 ′ -TACGTATTCCAATGCCTCTCCAACGATTGAC
TTGGTAGCAGACATAGGCCACTAGTGGATCTG-3 ′ ) 
which target integration at the  ERG11 promoter. The result-
ing isolate, DSY3899, was next used for deletion of the 
major effl ux transporters  PDR5 . This was accomplished by 
transformation with a PCR-generated fragment obtained 
with the template pFA6a-His3MX6 [17] and primers 
PDR5F (5 ′ -AAGTTTTCGTATCCGCTCGTTCGAAAGA 
CTTTAGACAAAACGGATCCCCGGGTTAATTAA-3 ′ ) 
and PDR5R: (5 ′ -TCTTGGTAAGTTTCTTTTCTTAAC-
CAAATTCAAAATTCTAGAATTCGAGCTCGTTTAAA 
C-3 ′ ). The resulting isolate was named DSY3961. 
 Induction of the cyp51A cDNAs expression from 
A. fumigatus in S. cerevisiae 
 A. fumigatus RNA was obtained from 16-h cultures as previ-
ously described [18]. A. fumigatus  cyp 51A cDNAs fl anked 
by pYES2/CT regions for homologous recombination in 
 S. cerevisiae were amplifi ed by PCR using the set of 
primers Cy51F (5 ′ -ACTACTAGCAGCTGTAATACGACT-
CACTATAGGGAATATTAAGCTTAAAATGGTGTCGAT-
GCTATTGCTCACGG-3 ′ ) and Cy51R (5 ′ -AGGGTTAGG 
GATAGGCTTACCTTCGAAGGGCCCTCTAGACTCGAG 
CTTGGATGTGTCTTTAGAACGCTT-3 ′ ). pYES2/CT con-
tains a polyhistidine (6xHis) tag for protein tagging at 
C-terminal end. Strain DSY3961 was transformed with 
5  μ l of digested plasmid and 5  μ l of the  A. fumigatus  cyp 51A 
previously amplifi ed by PCR in order to perform homolo-
gous recombination in  S. cerevisiae . Transformants were 
selected onto YNB-ura. To verify the system 4  μ l of liquid 
YNB-ura overnight cultures (fi ve 10-fold serial dilutions 
starting with OD   0.4) of DSY3961 and DSY3961  
 CM237cDNA were spotted in YNB-ura plates with galactose 
(2%) in the absence or presence of doxycycline (2  μ g/ml). 
 After transformation with each  A. fumigatus cDNA 
allele, 20 transformants were grown overnight in YNB-ura 
liquid media. Each transformant was screened for  erg11 
function complementation by inoculating 4  μ l of the yeast 
cultures in YNB-ura agar plates containing galactose (2%), and with and without doxycycline (2  μ g/ml). cyp51 A genes 
were amplifi ed and sequenced for verifi cation. 
 Inmunoblots 
 Protein extracts for immunoblotting were prepared by 
alkaline extraction from overnight cultures induced with 
galactose. Briefl y, cells were resuspended in an Eppendorf 
tube with 1 ml water and 150  μ l of a solution containing 
1.85 M NaOH and 7.5%  β mercaptoethanol. This mixture 
was incubated on ice for 10 min. Proteins were then 
precipitated with 150  μ l of a 50% trichloroacetic acid 
solution and the suspension was left on ice for another 
10 min. Precipitated proteins were centrifuged at maximal 
speed in a microcentrifuge for 5 min. The sediment was 
resuspended in 100  μ l of loading buffer (40 mM Tris-HCl 
[pH 6.8], 8 M urea, 5% sodium dodecyl sulfate [SDS], 
0.1 M EDTA, 1%  β mercaptoethanol, and 0.1 mg/ml 
bromophenol blue) and incubated at 37 ° C for 30 min. 
Non-solubilized material was eliminated by a centrifuga-
tion step for 10 min. Ten microliters of solubilized yeast 
proteins was separated by 10% SDS-polyacrylamide 
gel electrophoresis and transferred by Western blotting 
onto a nitrocellulose membrane. Immunodetection was 
performed with a polyclonal mouse anti His-tag antibody 
as previously described [19,20]. 
 E-test Susceptibility testing 
 Susceptibility testing to azoles was performed with the 
E-test using the selective media YNB-ura, galactose and 
doxycycline. Standardization of growth conditions were 
performed prior to evaluating the  in vitro azole drug 
susceptibility testing of individual  S. cerevisiae clones 
expressing each of the different  cyp51 A cDNAs. Yeast cul-
tures were grown overnight in YNB-ura with galactose 
(2%) and diluted to a density of 1 McFarlan. The clones 
were tested by E-test for fl uconazole (Pfi zer S.A., Madrid, 
Spain), itraconazole (Janssen Pharmaceutical S.A., Madrid, 
Spain), voriconazole (Pfi zer S.A.) and posaconazole 
(Merck  & Co, Madrid, Spain) in YNB-ura with galactose 
(2%) and doxycycline (2  μ g/ml). Plates were incubated at 
30 ° C. At least two clones for each  cyp51 A mutation, except 
for DSY3961  CM2162cDNA, were tested in order to 
average differences due to different copy number of plas-
mids between clones. The test was repeated at least two 
times. 
 Statistical analysis 
 MIC values were converted to log2 values to get a 
normalized distribution. The signifi cance of the differences 
in MICs was determined by Student ’ s  t test (unpaired, © 2011 ISHAM, Medical Mycology, 49, 276–284
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signifi cant. 
 Results 
 ERG11 conditional expression in S. cerevisiae 
 The functional complementation of  S. cerevisiae  ERG11 
with the different  cyp 51A alleles from the  A. fumigatus 
azole-susceptible and azole-resistant strains was accom-
plished using the tetracycline regulatable system described 
in the methods section [15,16]. To facilitate azole suscep-
tibility testing of individual  S. cerevisiae clones expressing 
each of the different  cyp51 A cDNAs, a yeast mutant lack-
ing the major effl ux transporter ( PDR 5), and thus hyper-
susceptible to azole antifungals, was fi rst constructed 
(DSY3961). The system was fi rst verifi ed comparing the 
growth of the strain DSY3961 and the strain 
DSY3961  CM237cDNA carrying  A. fumigatus wild type © 2011 ISHAM, Medical Mycology, 49, 276–284allele, in YNB-ura with galactose (2%) with and without 
doxycycline. Strain DSY3961 alone was unable to grow 
when doxycycline was added to the media, demonstrating 
the essential nature of  ERG11 in  S. cerevisiae and its func-
tional complementation by  A. fumigatus  cyp 51A alleles 
(Fig. 1A). 
 Expressing A. fumigatus cyp51A alleles in S. cerevisiae 
 Functional complementation of  ERG11 by  cyp 51A alleles 
was performed by turning off the expression of  ERG11 
with doxycycline and inducing the expression of  cyp 51A 
cDNAs from  A. fumigatus controlled by the  GAL1 pro-
moter with 2% galactose. After co-transformation of 
 cyp 51A with pYES2/CT, transformants were screened for 
each  Aspergillus cDNA background. All  A. fumigatus 
cyp 51A alleles could functionally complement the absence 
of  ERG11 (Fig. 1B). Figure 1C illustrates Cyp51Ap immu-
nodetection for clones expressing each  cyp51 A allele.  Fig. 1 (A) Serial dilutions of DSY3961 and DSY3961  CM237cDNA in YNB-ura with galactose (2%) in the absence or presence of doxycycline. 
(B) DSY3961 cDNAs mutated clones screening in YNB-ura with galactose (2%) in the absence or presence of doxycycline. (C) Inmunodetection of 
Cyp51A proteins for DSY3961  (1) CM237cDNA, (2) CM2158cDNA, (3) CM2159cDNA, (4) CM2161cDNA, (5) CM2162cDNA, (6) CM2164cDNA, 
(7) CM2266cDNA, (8) ITZ8cDNA, and (9) Pw6cDNA. Number (10) is the negative control (DSY3961  vector pYES2/CT). 
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responding  A. fumigatus strain cDNAs, i.e., CM237, 
CM2158, CM2159, CM2161, CM2162, CM2164, CM2266, 
ITZ8, and Pw6. 
 PCR amplifi cation and sequencing of  cyp 51A from the 
selected clones confi rmed that all of them conserved their 
original sequence and matched with wild type (azole-
susceptible)  A. fumigatus  cyp 51A sequences. One of the 
clones expressing CM2161cDNA and Pw6cDNA exhib-
ited a nucleotide change compared with their original 
 cyp 51A sequence, thus resulting in non-synonymous but 
on a non-conserved region of the protein (H350Y and 
A435T, respectively). 
 Role of A. fumigatus cyp51A alleles in azole resistance 
 As expected, all clones showed high fl uconazole MICs, 
which is in agreement with the intrinsic resistance of 
 A. fumigatus to this azole. There were marked differences 
between the E-test MICs values for DSY3961  CM237cDNA 
clones (expressing  A. fumigatus wild type  cyp 51A) and all 
of those expressing the  cyp 51A mutated alleles from 
A. fumigatus resistant strains. Some representative examples 
are shown in Fig. 2. 
 In general, all clones with  cyp 51A mutated alleles 
reproduced the susceptibility pattern of their corresponding 
 A. fumigatus parental strain (Table 1). Azole susceptibility 
values obtained for the full set of  S. cerevisiae clones are 
plotted in Fig. 3. 
 A. fumigatus resistant strains have an indistinct pattern of 
resistance to itraconazole with MICs   8  μ g/ml. However, 
differences in itraconazole susceptibility were noticeable in 
 S. cerevisiae cells, specially those expressing alleles with 
amino acid change at G54E, G54V, G54W and M220K (Figs. 
2 and 3). Regarding voriconazole, while the highest MIC 
values were obtained with  A. fumigatus isolates CM2158, 
CM2159 and PW6, only  S. cerevisiae clones expressing 
alleles from CM2159 (M220K) and PW6 (M220I) displayed 
higher MICs to voriconazole as compared to the wild type. 
Given that the detection limit for the E-test voriconazole 
MIC assay is 0.002  μ g/ml, our analysis could not detect 
any differences below this detection limit. Consistent with 
the  cyp51 A genetic background of CM2266 (G54W), 
the clones DSY3961  CM2266cDNA (G54W) reached the 
highest posaconazole MICs values, followed by clones car-
rying Cyp51Ap mutated alleles G54V, G54E and M220K 
(Table 1). In contrast, clones with changes at position M220T 
(DSY3961  CM2164cDNA) yielded the lowest MICs to 
posaconazole with no statistical signifi cance with the wild 
type  cyp 51A (Figs. 2 and 3). 
 Slight differences in MICs values of clones carrying the 
same  cyp 51A alleles were observed (Fig. 3). These varia-
tions could be attributed to the different number of copies of plasmids expressing the  cyp51 A. Nevertheless, the 
statistical analysis showed that differences were signifi cant 
( P value of   0.05) in most cases. 
 Discussion 
 Strains of  A. fumigatus are uniformly susceptible to the 
second-generation triazole drugs itraconazole, voricon-
azole, and posaconazole [8]. Resistance to antifungal drugs 
is a recognized problem occurring at a low frequency, 
although, resistance percentages between 6% and 12% 
were reported in some countries [6,21]. Secondary resis-
tance to azoles involving acquisition of resistance in a sus-
ceptible strain accounts for all resistance in  A. fumigatus. 
This resistance refl ects genetic changes responsible for spe-
cifi c resistance mechanisms. The molecular mechanisms 
underlying azole resistance has been well documented in 
 A. fumigatus . The initial fi nding was the existence of two 
different genes in  A. fumigatus , encoding two different 
14- α sterol demethylase proteins ( cyp 51A and  cyp 51B) 
[22]. However, it seems that Cyp51A is responsible for the 
basic susceptibility to azole drugs [10] and only  cyp51 A 
point mutations have been proven to be responsible for the 
azole resistance in  A. fumigatus. Basically, these point 
mutations confer three different antifungal susceptibility 
profi les: (i) cross resistance to itraconazole and posacon-
azole linked to amino acid substitutions at glycine 54 
(G54) [12,23,24]; (ii) a pattern of itraconazole resistance 
and high voriconazole, ravuconazole and posaconazole 
MICs linked to amino acid substitutions at methionine 220 
(M220) [13]; and (iii) a pattern of multiple azole-cross-
resistance associated with a higher  cyp 51A expression pro-
duced by insertion of a 34 bp tandem repeat sequence in 
the  cyp 51A gene promoter in combination with an amino 
acid substitution at Cyp51A leucine 98 (TRL98H) [14]. 
 Moreover, different azole resistance profi les can be 
attributed not only to the amino acid position but also to 
the amino acid change at each position (Table 1). In an 
effort to understand the particular contribution of each 
amino acid change to azole resistance, we have applied a 
complementation system to study  A. fumigatus genes that 
can functionally complement yeast essential genes. Par-
ticularly, the promoter  tet O (doxycycline repressible) was 
used in this work to control the expression of  ERG11 in 
S . cerevisiae [15,16] and evaluate differences in azole sus-
ceptibility between  A. fumigatus  cyp 51A alleles bearing 
the different point mutations. A similar approach has just 
been reported to characterize the impact of induced muta-
tions in the  Mycosphaerella graminicola 14- α eburicol 
demetilase on azole sensitivity [25]. Among  A. fumigatus 
resistance mechanisms described above, we have focused 
on the amino acids changes at Cyp51A position G54 and 
M220. For obvious reasons, the third mechanism (TRL98H) © 2011 ISHAM, Medical Mycology, 49, 276–284
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  Fig. 2  E-test susceptibility testing to itraconazole (ITC), voriconazole (VCZ) and posaconazole (POS) for DSY3961  CM237cDNA carrying wild 
type allele (WT), and representative clones bearing different Cyp51Ap alleles: M220K, M220T, G54W and M220I. © 2011 ISHAM, Medical Mycology, 49, 276–284
 282 Alcazar-Fuoli  et al .  
 Fig. 3 Plots of itraconazole (A) voriconazole (B) and posaconazole (C) MIC values for all  Saccharomyces cerevisiae clones (DSY3961) expressing 
the indicated mutated cyp 51A alleles. Means are indicated by horizontal bars. © 2011 ISHAM, Medical Mycology, 49, 276–284
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verifi ed using this approach. 
 Each mutated cyp51 A alleles contributed in a different 
way to azole resistance when itraconazole, posaconazole 
or voriconazole MICs were studied. In general, all clones 
bearing mutated alleles reproduced the susceptibility 
pattern of their original genetic background (Table 1 and 
Fig. 3). These fi ndings verifi ed that each amino acids 
change seems to have a different implication on azole drug 
resistance. It is noteworthy that using this system we could 
detect differences in ITC levels of susceptibility (Figs. 2 
and 3), while that is not possible when testing ITC-resistant 
A. fumigatus strains (Table 1) whose MICs are consistently 
  8 mg/l [9]. 
 The explanations for these results are possibly due to 
the way the drug interacts with its target and the conforma-
tional behaviour of the protein bearing the different amino 
acid changes. In that sense, Cyp51A homology models 
have already predicted different drug-protein interactions 
depending on the azole drug [26,27] and also the amino 
acid changes at Cyp51A [26,28]. These models predicted 
that G54 and M220 are located in loops in close proximity 
to the opening of channel 2. A change at G54, which is 
situated near to entry of the substrate access channel, has 
a dramatic effect on itraconazole and posaconazole. These 
two antifungals have long chains that may interact with the 
substrate access channel at different locations. Remarkably, 
when G54 was substituted by the large and hydrophobic 
tryptophan residue (W), it seems that this change is suffi -
cient to interfere with the access to channel 2, which then 
prevents docking of posaconazole and/or itraconazole [26]. 
Modifi cations at G54 would not have any impact on the 
binding of voriconazole which has a more compact chem-
ical structure than itraconazole or posaconazole. In con-
trast, mutations altering  A. fumigatus Cyp51Ap at position 
M220 would cause an increase of MICs values to voricon-
azole [23,26]. It is encouraging that the results presented 
here compare well with the structural predictions. Clones 
expressing alleles with the amino acid change at G54W 
showed the highest MICs values to itraconazole and posa-
conazole, followed by the amino acids changes G54E and 
G54V. These results are also in good agreement with the 
MICs values for the  A. fumigatus CM2266 (G54W) clinical 
strains which has been shown to be highly resistant to 
posaconazole  in vitro and  in vivo [9,29]. 
 Among the substitutions at position M220 (M220K, 
M220I, M220T), the M220K change contributed to the 
highest MICs values to itraconazole and posaconazole. 
Because lysine (K) is the largest residue among the three 
amino acids, this result could be expected from a structural 
point of view. Lysine has a basic lateral chain and might 
affect the azole docking in a way that also results in 
decreased susceptibility to itraconazole and posaconazole. © 2011 ISHAM, Medical Mycology, 49, 276–284However, modifi cations M220I and M220T had less impact 
on itraconazole resistance and particularly a changed 
M220T had no effect at all on posaconazole susceptibility. 
Finally, only clones bearing the Cyp51Ap substitution 
M220K and M220I showed increased MICs to voricon-
azole, which is similar to the azole resistance profi le of 
 A. fumigatus strains with these specifi c amino acid substi-
tutions and correlates with the Cyp51Ap homology mod-
els. Therefore, we can conclude that the different 
substitutions at M220 would affect drug-target interactions 
depending either on the shape, size and nature of the 
substituted amino acid or on the azole drug. 
 In conclusion, we have designed a system to evaluate 
functional complementation of  ERG11 in  S. cerevisiae . 
This system has been implemented for the fi rst time to 
assess differences in azole susceptibility between  A. fumig-
atus  cyp 51A alleles with different point mutations (result-
ing in eight different amino acid substitutions at G54 and 
M220 in  Aspergillus fumigatus Cyp51A) that have been 
described as responsible for clinical azole resistance. This 
system is a valuable tool that can be used to address and 
predict resistance mechanism in  A. fumigatus . It also pro-
vides opportunities to test other resistance mechanisms 
where others genes of interest could be expressed in a 
similar manner. Moreover, this system could probe amino 
acid changes/intrinsic resistance of Cyp51A from other 
fi lamentous fungi which are not easily genetically tractable 
i.e.,  Scedosporium spp.,  Fusarium spp. and many  Mucor-
ales spp., Finally, the system designed here can be used to 
test the effi cacy of additional azole drugs with respect to 
existing  cyp 51A mutations, or de novo inhibitors synthesis 
to improve the treatment of infections produced by 
A. fumigatus . 
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